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Abstract
Tumors have aberrant proteomes that often do not match their corresponding transcriptome profiles. One possible cause of 
this discrepancy is the existence of aberrant RNA modification landscapes in the so-called epitranscriptome. Here, we report 
that human glioma cells undergo DNA methylation-associated epigenetic silencing of NSUN5, a candidate RNA methyl-
transferase for 5-methylcytosine. In this setting, NSUN5 exhibits tumor-suppressor characteristics in vivo glioma models. 
We also found that NSUN5 loss generates an unmethylated status at the C3782 position of 28S rRNA that drives an overall 
depletion of protein synthesis, and leads to the emergence of an adaptive translational program for survival under condi-
tions of cellular stress. Interestingly, NSUN5 epigenetic inactivation also renders these gliomas sensitive to bioactivatable 
substrates of the stress-related enzyme NQO1. Most importantly, NSUN5 epigenetic inactivation is a hallmark of glioma 
patients with long-term survival for this otherwise devastating disease.
Keywords Glioma · Epitranscriptomics · RNA methylation · Clinical outcome
Introduction
Cellular homeostasis requires accurate regulation of protein 
levels [46]. In pathological states, such as cellular trans-
formation, the proteome undergoes massive changes [16]. 
Much effort has been devoted to the study of how events 
leading to aberrant RNA transcription regulation generate 
cancer transcriptomes [35]. However, there is an important 
disjunction between overall transcriptional activity and pro-
tein abundance [49]. Defects in protein degradation, such 
as those affecting the von Hippel–Lindau ubiquitin ligase 
complex [52] and the endoplasmic reticulum-associated 
protein degradation pathway [25], might partially explain 
this discrepancy, but a picture has emerged of how protein 
levels of key cancer genes are dysregulated by alterations in 
de novo protein synthesis [43, 45, 48]. Aberrant translational 
control occurs during the origin, maintenance, and progres-
sion of tumoral cells [43, 45, 48]. The enhanced growth of 
cancer cells often requires an increase in global protein syn-
thesis that it is strongly linked to increased ribosome activity 
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[43, 45, 48]. However, it has recently become clear that 
this picture is even more complex than previously thought, 
because oncogenic signaling and stress-related conditions 
can enhance translation of specific transcripts [2, 47], even 
in the context of restricted overall protein synthesis [5, 6].
Although several cellular factors may be involved in the 
aforementioned phenotypes with respect to RNA transla-
tion and protein production, it is likely that alterations in 
components of the machinery of ribosome biogenesis and 
protein synthesis play a central role in these processes. In 
this regard, mutations in ribosomal proteins such as RPS19, 
RPL5, RPS26, and RPL11 occur in Diamond–Blackfan ane-
mia, a syndrome that it is characterized by increased suscep-
tibility to cancer [7]. Interestingly, in X-linked dyskeratosis 
congenita (X-DC), another syndrome related to increased 
cancer risk, the main mutated gene is DKC1 [18], a pseu-
douridine synthase that modifies ribosomal RNA (rRNA) at 
the post-transcriptional level [37, 53]. The defect in DKC1 
gives rise to an altered internal ribosome entry site-depend-
ent translational program [3, 4, 21, 53]. Most importantly, in 
addition to pseudouridine, ribosomal RNA exhibits another 
post-transcriptional modification: the presence of 5-methyl-
cytosine [11, 39]. Neither the existence of distorted rRNA 
5-methylcytosine profiles in human cancer nor the role of 
RNA methyltransferases for 5-methylcytosine in rRNA for 
cellular transformation has been properly characterized [11, 
39]. Here, we show that NSUN5, acting as the RNA meth-
yltransferase for the C3782 position of human 28S rRNA, is 
an enzyme with tumor-suppressor properties that undergoes 
epigenetic loss in gliomas, leading to an overall deficiency in 
protein synthesis and the initiation of a specific translational 
program for adaptation to cellular stress conditions. Most 
important, and as it also occurs with the isocitrate dehydro-
genase (IDH1) mutations [32, 50], the presence of NSUN5 
DNA methylation-associated silencing in human gliomagen-
esis identifies patients with good clinical outcome, which is 
an exceptional feature of people affected by this tumor type.
Materials and methods
Cell lines
Human glioma cell lines DBTRG-05MG, M059J, A172, 
and LN229 were purchased from the American Type Cul-
ture Collection; CAS-1 was obtained from The Biological 
Bank of the IRCCS Azienda Ospedaliera Universitaria San 
Martino—IST Istituto Nazionale per la Ricerca sul Cancro; 
and KS-1 was purchased from the Japanese Collection of 
Research Bioresources Cell Bank. Cell lines were all cul-
tivated in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% v/v fetal bovine serum (FBS) 
(Innovative, Novi, MI) and 1% v/v penicillin/streptomycin 
(Gibco). Human grade III glioma cell lines SW1088 and 
BT142 mut/- were purchased from the American Type 
Culture Collection and MOG-G-CCM was purchased from 
Sigma-Aldrich. These cell lines were cultivated regarding to 
suppliers recommandations. All cell lines were authenticated 
by short tandem repeat profiling (LGS Standards SLU) and 
tested for the absence of mycoplasma.
DNA methylation analyses
DNA methylation status of the 5′-end promoter-associated 
CpG Island of the NSUN5 gene was determined by bisulfite 
genomic sequencing and DNA methylation microarrays. For 
all methods, genomic DNA was bisulfite-converted using an 
EZ DNA Methylation Gold kit (Zymo Research, Orange, 
CA, USA). For bisulfite genomic sequencing, a minimum 
of eight single clones were interrogated for each sample 
and the methylation frequency was calculated in each case. 
Results were analyzed with BioEdit software and methyl-
ated cytosines were mapped using BSMap software. NSUN5 
CpG methylation status in pediatric gliomas was determined 
by pyrosequencing using the primer sequences shown in the 
supplementary Key Resources Table. The DNA methylation 
array used was the Infinium HumanMethylation450 Bead-
Chip (Illumina). Raw fluorescence intensity values were nor-
malized with Illumina Genome Studio software (V2011.1) 
using ‘control normalization’ with background correction. 
Normalized intensities were then used to calculate DNA 
methylation levels (beta values).
Expression analyses
For real-time quantitative reverse transcription-PCR experi-
ments, total RNA was extracted using the SimplyRNA kit 
(Promega) on a Maxwell RSC device (Promega) and ret-
rotranscribed using the ThermoScript RT-PCR system 
(ThermoFisher) with oligo(dT) primers. The reaction was 
carried out following the methods for the use of SYBR 
Green (Applied Biosystems), and GAPDH was used as 
housekeeping genes to enable normalization. Primers for 
qPCR are listed in the supplementary Key Resources Table. 
Reactivation treatments with the demethylating agent 5-aza-
2′-deoxycytidine (AZA; Sigma) were performed at 0.5 µM 
for 72 h. For immunoblotting assays, we extracted cell pel-
lets and brain white matter samples with 300 µL of RIPA 
buffer containing protease and phosphatase inhibitors cock-
tail cOmplete™ (Roche). Antibodies used in this study are 
described in supplementary Key Resources Table.
NSUN5 transfection
The cDNA sequence of NSUN5 containing a FLAG-
Tag in the amino-terminal end was cloned into the 
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pLVX-IRES-ZsGreen1 expression plasmid (Clontech 
Laboratories) between the EcoRI and XbaI restriction 
sites. Lentiviruses containing this construct were produced 
by cotransfecting HEK-293T cells with the recombinant 
pLVX-IRES-ZsGreen1, psPAX2 (Addgene), and pMD2.G 
(Addgene), using  jetPRIME® Transfection Reagent (Poly-
plus Transfection) and following the supplier instructions. 
The transfection cocktail was removed after 6 h and replaced 
by fresh medium. After 72 h, viral containing supernatant 
was collected, 0.45 µM-filtered, and stored at 4 °C before 
infection. The recombinant product was randomly inserted 
by lentiviral transduction in the genome of the A172 and 
LN229 glioma cell lines. After 5 passages, the green fluo-
rescent cells were sorted by FACS and cultured in DMEM 
medium supplemented with 10% FBS and 1% v/v penicillin/
streptomycin (Gibco). For primers sequences, please refer to 
supplementary Key Resources Table.
NSUN5 depletion
Four different sequence gene-specific short hairpin RNA 
molecules (shRNAs) for NSUN5 mRNA were designed and 
transduced into DBTRG-05MG and CAS-1 glioma cell line 
(for sequences please refer to supplementary Key Resources 
Table). shRNA against the MSS2 yeast mRNA (not present 
in mammals) was used as scrambled (control). All shRNA 
molecules were ligated into pLVX-shRNA2-ZsGreen plas-
mid (Clontech). 10 ug of each encoding plasmid was mixed 
with 7.5 μg of ps-PAX2 and 2.5 μg of PMD2.G plasmid 
(Addgene), using  jetPRIME® Transfection Reagent (Poly-
plus Transfection). Upon 10 min of RT incubation, the trans-
fection mix was added dropwise on a 10 cm culture plate 
containing HEK293-TLV lentiviral packaging cells at 80% 
confluence. After 72 h, medium with high-titer lentiviral 
particles was 0.45 μm filtered. DBTRG-05MG and CAS-1 
glioma cell lines were cultured in virus containing medium 
for 24 h. After 5 passages, the green fluorescent cells were 
sorted by FACS and cultured in DMEM medium supple-
mented with 10% FBS and 1% v/v penicillin/streptomycin 
(Gibco).
Brain tumor xenografts
IVIS images
All mouse experiments were approved and performed in 
accordance with the guidelines of the Institutional Animal 
Care Committee of the Vall d’Hebron Research Institute. 
1 × 106 cells were stereotactically inoculated into the cor-
pus striatum of the right brain hemisphere of 9-week-old 
athymic mice Nude-Foxn1nu mice (Charles River Labora-
tories). To estimate the size of tumors, the luciferase activity 
of inoculated tumor cells was quantified in a Xenogen–CCD 
camera from IVIS. All mouse experiments were approved 
by and performed according to the guidelines of the Insti-
tutional Animal Care Committee of the Vall d’Hebron 
Research Institute in agreement with the European Union 
and national directives. 3 × 105 A172 and LN229 (EV or 
NSUN5) or DBTRG-05MG (scramble or shNSUN5) cells 
were stereotactically inoculated into the corpus striatum of 
the right brain hemisphere (1 mm anterior and 1.8 mm lat-
eral to the lambda; 2.5 mm intraparenchymal) of 8-week-old 
Balb/c nude mice (Janvier Labs). We inoculated 7 animals 
per group. Tumor progression was monitored by biolumines-
cence measurements using the Xenogen  IVIS® Spectrum. 
Mice were euthanized at day 17 after inoculation.
Xenografts growth
All mouse experiments were approved and performed in 
accordance with the guidelines of the Institutional Animal 
Care Committee of the Bellvitge Biomedical Research Insti-
tute. For tumor growth into the brain, 3 × 105 or 1.5 × 106 
cells, respectively, for LN229 (EV or NSUN5) and DBTRG-
05MG (scramble or shNSUN5) were inoculated into the cor-
pus striatum of 9 (scramble and shNSUN5) or 10 (EV and 
NSUN5) mice for each cell line individually.
NSUN5 immunoprecipitation and RT‑qPCR
Immunoprecipitations were carried out from total LN229 
extracts (transfected with empty vector or NSUN5) over-
night with 10  μl of Anti-Flag⨁ M2 Magnetic Beads 
(Sigma) in RIP buffer (150 mM KCl, 25 mM Tris pH7.4, 
5 mM EDTA, 0.5 mM DTT, 0.5% NP40, protease inhibi-
tors). Beads were then washed three times with RIP buffer, 
and 10% of beads were boiled in Laemmli buffer 1× and 
loaded on a protein gel to check immunoprecipitation effi-
ciency. The pulled-down RNA from the remaining 90% of 
beads was extracted by adding 1 mL of TRIzol⨁ Reagent 
(ThermoFisher). After phenol extraction and isopropanol 
precipitation, a DNase treatment step was performed, and 
the final pellet was resuspended in water. Equal amounts 
of each sample were then retrotranscribed and analyzed by 
quantitative PCR (Applied Biosystems 7900HT Fast Real-
Time PCR System). The equivalent amount of input RNA 
was processed in parallel to estimate pull-down efficiency.
RNA methylation analyses
RNA bisulfite conversion and sequencing was performed 
following Epigentek Methylamp RNA bisulfite conversion 
Kit instructions. The resulting bisulfite-modified RNA was 
converted in cDNA using the ThermoScript RT-PCR system 
(ThermoFisher) with random hexamer primers. PCR primers 
for the sequence of interest are available in supplementary 
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Key Resources Table. The amplicon PCR band was purified 
and ligated into  pGEM®-T Easy vector (Promega), trans-
formed, and sequenced as described previously in DNA 
methylation analyses. Bisulfite RNA deep-sequencing (Bis-
seq) was performed as described in Suppl. Methods.
Global determination of protein synthesis
Overall protein synthesis in the different experimental con-
ditions was assessed by the incorporation of O-propargyl-
puromycin (OP-Puro) into nascent proteins using the Click-
iT® OPP Reagent (Thermo Fisher) [5] and [3H] leucine 
incorporation.
Assessment of translational efficiency
Translational efficiency for each RNA was determined by 
normalizing the ribosome profiling deep-sequencing data 
(Ribo-seq) to transcript length and total transcript abundance 
according to deep-sequencing RNA transcriptome (RNA-
seq) data, as described in Suppl. Methods.
Gene functional‑enrichment analysis and sequence 
motifs recognition
Gene sets were used to perform a gene set over-representa-
tion analysis over the GO-biological processes and KEGG 
pathways included in the public GSEA signature database 
collections and the DAVID web service. The top gene clus-
ters resulting from the hypergeometric test with an FDR 
adjusted P value < 0.05 was finally considered. 5′UTR 
DNA sequences from selected genes were used to perform 
a motif recognition analysis. RegRNA 2.0 and FIMO soft-
ware from MEME suite 4.12.0 were used to perform CERT, 
TOP, PRTE, and uORF motif scanning. IRESPred web 
service and Infernal software were used to identify IRES 
motifs. G4-quadruplexes were identifies using QGRS Map-
per software.
Stable isotope labeling by amino acids in cell culture 
(SILAC)
SILAC was performed as previously described [25]. SILAC 
labeling was performed using SILAC-Lys8- Arg10-Kit 
media (Silantes). Peptide mixes were analyzed using an 
OrbitrapFusion Lumos mass spectrometer (Thermo Scien-
tific, San Jose, CA, USA) coupled to an EasyLC (Thermo 
Scientific (Proxeon), Odense, Denmark). All data were 
acquired with Xcalibur software v3.0.63. Proteome Discov-
erer software suite (v2.0, Thermo Fisher Scientific) and the 
Mascot search engine (v2.5, Matrix Science (1)) were used 
for peptide identification and quantification. Samples were 
searched against a SwissProt database containing entries 
corresponding to Human (version of April 2016) a list of 
common contaminants and all the corresponding decoy 
entries. Resulting data files were filtered for FDR < 1%.
Deoxynyboquinone 
and isobutyl‑deoxynyboquinone drug assays
IC50 studies in the glioma cell lines upon drug exposure 
were performed using the sulforhodamineB (SRB) assay. 
Briefly, 48 h after exposure to nine increasing concentra-
tions of deoxynyboquinone (2 nM–15 µM), culture medium 
was removed and 100 µL of 10% trichloroacetic acid was 
added to the wells to fix cells for 1 h at 4 °C. Cells were then 
washed twice with distilled water and stained with 100 µL of 
0.4% SRB in 1% acetic acid during 30 min, light-protected, 
and washed twice with 1% acetic acid. SRB was then solu-
bilized in Tris base (10 mM; pH 10.0) and 540 nm-optical 
density was determined using a microplate reader (Perkin 
Elmer Viktor 3).
Patients
DNA methylation data in the discovery set of glioma cases 
was collected from The Cancer Genome Atlas (TCGA) 
Data Portal (https ://tcga-data.nci.nih.gov/tcga/). For the 
initial glioma validation cohort, 115 formalin-fixed paraffin-
embedded (FFPE) tumor tissues from glioma patients were 
retrospectively collected in four different centers (Hospital 
Universitari de Bellvitge, Hospital Germans Trias i Pujol, 
Hospital Clínic de Barcelona and University Hospital Basel) 
from 1989 to 2018 and were histologically reviewed. Most 
of patients had received treatment based on temozolamide 
combined or not with radiotherapy, and molecular analyses 
of IDH1 mutational status and MGMT methylation were 
available. Co-deletion 1p19q status was only available in 23 
of the 115 cases. Patients gave their informed consent to par-
ticipate in the research, which had received ethical approval 
from the review board of each institution. The expanded 
glioma validation cohort included 303 additional glioma 
patients from which NSUN5 methylation, IDH1 mutation, 
co-deletion of 1p19q, MGMT methylation, and progression-
free survival are available [1, 22]. These cases had signed 
written informed consent and were histologically reviewed 
as described in the respective publications [1, 22].
Statistical analysis
The associations between variables were assessed by χ2 
tests, Fisher’s exact test, Mann–Whitney test, Welch’s t test, 
Wilcoxon paired test, or Spearman correlation whenever 
indicated. Kaplan–Meier plots and log-rank test were used 
to estimate Overall Survival (OS). Statistical analysis was 
performed using SPSS for Windows (Armonk, NY) and 
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GraphPad Prism 5 (La Jolla, CA) for Windows. P values 
less than 0.05 were considered statistically significant. All 
statistical tests were two-sided. Methylation and expression 
values for GBM and LGG TCGA primary tumor samples 
were obtained from the NCI’s Genomic Data Commons 
(GDC). The values corresponding to glioma cell lines were 
obtained from COSMIC cell line database. Correlations 
were obtained by calculating Spearman’s rank correlation 
test and the associated rho coefficient.
Data availability
All the obtained deep-sequencing data have been deposited 
at the SRA (https ://www.ncbi.nlm.nih.gov/sra) with the fol-
lowing links:
RNA-Seq: BioProject: PRJNA395552
https ://datav iew.ncbi.nlm.nih.gov/objec t/PRJNA 39555 
2?revie wer=60ndb 08i1g 6na5n koaai ad9a6 o
bsRNA-Seq: BioProject: PRJNA395575
https ://www.ncbi.nlm.nih.gov/biopr oject /39557 5
Ribo-Seq: BioProject: PRJNA395570
https ://www.ncbi.nlm.nih.gov/biopr oject /39557 0
Results
Identification of NSUN5 CpG island promoter 
hypermethylation‑associated transcriptional 
silencing in glioma cells
To identify candidate genetic and epigenetic defects in 
the proposed ribosomal RNA cytosine methyltransferases 
NSUN5, NSUN1 (28S rRNA C4447), and NSUN4 (12S 
mitochondrial rRNA C841) in human tumorigenesis, we first 
data-mined a collection of 1001 human cancer cell lines in 
which we had recently determined the exome mutational, 
transcriptomic, gene copy number, and DNA methylation 
profiles [20]. The available genomic data did not indicate the 
presence of NSUN5, NSUN1, or NSUN4 mutations, ampli-
fications, or deletions in the cell lines considered (Suppl. 
Dataset 1). Although genetic defects in the described genes 
were not found, transcriptional silencing by promoter CpG 
island hypermethylation is another mechanism for inactivat-
ing genes in human cancer [12]. The NSUN1 and NSUN4 
promoter-associated CpG islands were unmethylated in the 
cell lines studied (Suppl. Datasets 1b and c). In contrast, the 
NSUN5 promoter CpG island was methylated in 38% (21 
of 55) of the glioma-derived cell lines studied (Fig. 1a and 
Suppl. Dataset 1a). Data-mining of microarray expression 
results [20] showed that NSUN5 hypermethylation was asso-
ciated with transcript downregulation in the glioma cell lines 
(Fig. 1b). Beyond glioma-derived malignancies, the NSUN5 
promoter CpG island was mostly found to be unmethylated 
in the other tumor types available in our data set, with the 
exception of thyroid cancer (4 of 16, 25%), biliary tract (1 of 
5, 20%), autonomic ganglia (6 of 33, 18%), and soft-tissue 
sarcoma (3 of 23, 13%) (Fig. 1a and Suppl. Dataset 1a). The 
NSUN5 promoter CpG island was unmethylated in all the 
normal human tissues studied (Suppl. Dataset 1d).
Having identified the aforementioned NSUN5 CpG island 
methylation profiles, we studied in greater detail their asso-
ciation with the possible transcriptional inactivation of the 
NSUN5 gene at the RNA and protein levels in glioma cell 
lines. We performed bisulfite genomic sequencing of mul-
tiple clones in the glioblastoma cell lines DBTRG-05MG, 
MO59J, CAS-1, A172, LN229, and KS-1 using primers that 
encompassed the transcription start site-associated CpG 
island. We found the 5′-end region of NSUN5 of the LN229, 
A172, and KS-1 glioma cell lines to be hypermethylated 
in comparison with normal brain white matter (Fig. 1c), 
whereas the DBTRG-05MG, CAS-1, and MO59 J cells were 
unmethylated (Fig. 1c). These results validated the DNA 
methylation patterns obtained by the microarray approach 
(Fig. 1d). Normal astrocytes, fetal brain, and different brain 
regions (such as frontal cortex, posterior cingulate cortex, 
and hippocampus) were unmethylated for NSUN5 in all 
cases (Dataset 1e). Positive and negative technical controls 
for the DNA methylation assays are shown in Suppl. Data-
set 1f. Most notably, the NSUN5-hypermethylated glioma 
cell lines LN229, A172 and KS-1 minimally expressed 
the NSUN5 RNA transcript and protein, as determined by 
quantitative real-time PCR and western blot, respectively 
(Fig. 1e). Conversely, the glioma cell lines unmethylated at 
the NSUN5 promoter (DBTRG-05MG, CAS-1, and MO59J) 
expressed NSUN5 RNA and protein (Fig. 1e). Treatment 
of the methylated glioblastoma cell lines with the DNA-
demethylating agent 5-aza-2-deoxycytidine restored NSUN5 
expression at the RNA and protein levels (Fig. 1f) in asso-
ciation with hypomethylation events at the promoter CpG 
island (Suppl. Fig. S1a). We extend the study to three grade 
III glioma cell lines: BT142 mut/−, harboring a homozygous 
R132H mutation [26], and SW1088 and MOG-G-CCM, 
wild type for IDH1. We found DNA methylation-associated 
silencing of NSUN5 in BT142 mut/- cells, whereas the two 
remaining cell lines (SW1088 and MOG-G-CCM) were 
unmethylated and expressed NSUN5 (Suppl. Fig. S1b and 
c). Treatment of the methylated cell line BT142 mut/- with 
the DNA methylation inhibitor restored NSUN5 expression 
at the RNA and protein levels (Suppl. Fig. S1d). The study 
of 16 patient-derived xenograft (PDX) from primary glio-
mas engrafted in nude mice showed that NSUN5 was hyper-
methylated in three cases (19%). RNA was available for four 
cases (two unmethylated and two methylated) and NSUN5 
hypermethylation was associated with diminished transcript 
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levels (Suppl. Fig. S1e). Overall, these results indicate that 
cancer-specific promoter CpG island hypermethylation-asso-
ciated silencing of the NSUN5 gene occurs in glioma cells.
Once we had demonstrated the existence of NSUN5 
CpG island hypermethylation-associated transcriptional 
loss in glioma cell lines, we studied its contribution to the 
growth of these cells. To this end, we analyzed the effect 
of the restoration of NSUN5 expression in the NSUN5-
hypermethylated glioblastoma cell lines LN229 and A172. 
Upon efficient transfection of NSUN5 (Fig. 2a), we studied 
the growth of glioma cells in vivo by performing intrac-
erebral mouse xenotransplantation experiments using 
LN229 and A172 GFP-Luc cell lines, and quantified tumor 
growth over time by measuring luciferase activity. Tumors 
obtained from NSUN5-transfected LN229 and A172 cell 
lines showed a significant reduction in size at 10 and 17 day 
post-inoculation in comparison with the respective empty-
vector-transfected cells (Fig. 2b, c). In the reverse experi-
ment, we observed that tumors arising from unmethylated 
DBTRG-05MG cells undergoing NSUN5 shRNA-mediated 
Fig. 1  Transcriptional silencing of NSUN5 by promoter CpG island 
hypermethylation in human glioma cells. a Percentage of NSUN5 
methylation in the Sanger panel of cancer cell lines by tumor type. 
b NSUN5 methylation is associated with loss of the transcript in the 
glioma cell lines from Sanger (n = 48). Correlation analysis between 
methylation beta values and expression Z-score are shown. The P 
value corresponding to Spearman’s rank correlation test and the asso-
ciated rho coefficient are indicated in the figure. c Bisulfite genomic 
sequencing of NSUN5 promoter CpG Island in glioma cells lines and 
brain white matter. CpG dinucleotides are represented as short verti-
cal lines and the transcription start site (TSS) is represented as a long 
black arrow. Single clones are shown for each sample. Presence of an 
unmethylated or methylated cytosine is indicated by a white or black 
square, respectively, and percentage of methylation is indicated on 
the right. d DNA methylation profile of the CpG island promoter for 
the NSUN5 gene analyzed by the 450 K DNA methylation microar-
ray. Single CpG absolute methylation levels (0–1) are shown. Green, 
unmethylated; red, methylated. Data from the studied six glioma 
cell lines, brain white matter and nineteen normal brain samples are 
shown. e NSUN5 expression levels in glioma cell lines determined 
by real-time PCR (data shown represent mean ± S.D. of biological 
triplicates) and western blot. f Expression of the NSUN5 RNA tran-
script and protein was restored in the A172, LN229 and KS-1 cells by 
treatment with the demethylating drug 5-aza-2′-deoxycytidine (AZA). 
Data shown represent the mean ± S.D. of biological triplicates and P 
values were obtained by the Mann–Whitney test. **P < 0.01
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depletion showed a significant increase in size in comparison 
with those originated from scramble shRNA cells (Suppl. 
Fig. S2a, b and c). The study of subcutaneously injected 
cancer cells into nude mice provided similar results: tumors 
originated from NSUN5-transfected LN229 cells had a 
significantly lower volume and weight than empty-vector-
transfected-derived tumors (Fig.  2d), whereas NSUN5 
shRNA-mediated depletion in the unmethylated DBTRG-
05MG cell line increased the volume and weight of the 
derived tumors (Fig.  2e). Comparing NSUN5 shRNA-
depleted vs scramble DBTRG-05MG cells injected ortho-
topically in the brain of nude mice, we found that NSUN5 
downregulation was associated with shorter overall survival 
(Suppl. Fig. S2e), whereas transfection-mediated recovery 
of NSUN5 expression in LN229 hypermethylated cells was 
associated with longer overall survival (Suppl. Fig. S2d). 
NSUN5 restoration by transfection in hypermethylated glio-
blastoma cells also diminished proliferation in vitro (Suppl. 
Fig. S3a), whereas its shRNA-mediated downregulation in 
NSUN5 unmethylated cells increased cell viability (Suppl. 
Fig. S3b). The glioma-related genes IDH1, TET1, or TET3 
are wild type in the studied cells lines (COSMIC) and we 
observed a similar expression of the three proteins in the 
three NSUN5 unmethylated and methylated glioma cell lines 
(Suppl. Fig. S3c). The expression of these proteins did not 
change upon NSUN5 restoration in LN229 cells or depletion 
Fig. 2  Restoration of NSUN5 impairs glioma tumor growth in vivo. a 
Western blot to show efficient restoration of NSUN5 protein expres-
sion upon stable transfection in A172 and LN299 glioma cells and 
efficient depletion of NSUN5 protein expression in NSUN5-shRNA 
DBTRG-05MG glioma cells. EV empty vector. An equal number of 
the indicated A172 and LN299 cells populations were stereotactically 
inoculated into the brain of athymic mice. The size of the tumors was 
estimated at 10 and 17  days post-inoculation (DPI) by the quantifi-
cation of luciferase activity in the tumor cells. b Scatter plots show-
ing the individual size of the indicated LN229 and A172 tumors after 
10 and 17 DPI. c Representative images of the luciferase signal from 
mice inoculated with the indicated LN229 and A172 tumors after 
17 DPI. d LN229-EV and LN229-NSUN5 cells were injected in the 
left or right flank of 10 mice, respectively. Tumor volume measured 
over time (left panel) and tumor weight upon sacrifice (right panel) 
are shown. P values obtained by Student’s t test. Error bars show 
means ± s.d. e Scramble and NSUN5-shRNA-depleted DBTRG-
05MG cells were injected in the left or right flank of 10 mice, respec-
tively. Tumor volume measured over time (left panel) and tumor 
weight upon sacrifice (right panel) are shown. P values obtained by 
Student’s t test. Error bars show means ± s.d
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in DBTRG-05MG cells (Suppl. Fig. S3c). These results sug-
gest that NSUN5 has a specific tumor-suppressor role in 
gliomas.
NSUN5 is the RNA methyltransferase for the C3782 
position of 28S rRNA
The activity and targets of NSUN5 in human cells have not 
been formally identified, but the yeast S. cerevisiae (Rcm1) 
[13, 38, 40] and worm C. elegans (nsun-5) [38] homologues 
are responsible for methylating C2278 in the 25S rRNA and 
C2381 in the 26S rRNA, respectively. Phylogenetic analyses 
show that the C2278 and C2381 positions in the yeast and 
worm 25S and 26S rRNAs, respectively, correspond to the 
C3782 position of the human 28S rRNA (Fig. 3a). This site 
is placed in the vicinity of the peptidyltransferase center 
of the large ribosomal subunit [36, 38], suggesting that it 
is relevant for core ribosomal function. Thus, we set out 
to demonstrate that NSUN5 is responsible for methylating 
C3782 28S rRNA in our glioma models.
For this purpose, we first showed that 28S rRNA repre-
sents a binding target of NSUN5, since immunoprecipita-
tion of NSUN5 specifically retrieved this RNA sequence 
in the RNA pull-down assay (Fig. 3b). We next performed 
comparative bisulfite sequencing of multiple clones of the 
28S rRNA extracted from the NSUN5 unmethylated glio-
blastoma cell lines DBTRG-05MG, MO59J, and CAS-1, 
and the NSUN5 hypermethylated and transcriptionally 
silenced LN229, A172, and KS-1 glioblastoma cell lines. 
We observed that while the NSUN5-expressing DBTRG-
05MG, MO59J, and CAS-1 cells showed high levels of 
C3782 28S rRNA methylation, the LN229, A172, and KS-1 
cells undergoing NSUN5 epigenetic inactivation displayed a 
lack of C3782 28S rRNA methylation (Fig. 3c). Treatment 
of the NSUN5 methylated glioblastoma cell lines with the 
DNA-demethylating agent 5-aza-2-deoxycytidine not only 
restored NSUN5 expression (Fig. 1f), but also recovered 
C3782 28S rRNA methylation (Suppl. Fig. S4a). The LN229 
and A172 cells, showing NSUN5 epigenetic silencing, also 
recovered C3782 28S rRNA methylation upon restoration of 
NSUN5 activity by transfection (Fig. 3d). Importantly, we 
constructed an NSUN5 catalytic inert form due to the pres-
ence of multiple engineered mutations (Suppl. Fig. S4b and 
c) that was unable to restore C3782 28S rRNA methylation 
(Suppl. Fig. S4d). The mung bean nuclease protection assay 
(Suppl. Methods) confirmed the RNA bisulfite sequencing 
data for C3782 28S rRNA methylation (Suppl. Fig. S4e, 
f and g). LN229 cells with NSUN5 epigenetic loss were 
depleted for C3782 28S rRNA methylation in both nuclear 
and cytoplasmic fraction, whereas NSUN5 transfection 
restored the methylation status at both compartments (Suppl. 
Fig. S5a). To demonstrate the specificity of our experimen-
tal approach, we showed that the transfection of NSUN5 
in LN229 and A172 cells did not change the levels of the 
other two candidate human ribosome RNA methyltrans-
ferases, NSUN1 and NSUN4 (Suppl. Fig. S5b). We also 
studied the stable knockdowns of NSUN5 by the short hair-
pin RNA (shRNA) method in the NSUN5-expressing and 
unmethylated glioma cell lines DBTRG-05MG and CAS-
1. Upon effective NSUN5 shRNA-mediated downregula-
tion, we observed hypomethylation at the C3782 28S rRNA 
site in DBTRG-05MG and CAS-1 cells (Fig. 3e). The link 
between NSUN5 epigenetic silencing and C3782 28S rRNA 
hypomethylation was also observed in the grade III glioma 
cell lines: BT142 mut/- cells, harboring DNA methylation-
associated silencing of NSUN5, showed an unmethylated 
C3782 28S site, whereas SW1088 and MOG-G-CCM (both 
unmethylated and expressing NSUN5) showed a methylated 
C3782 28S rRNA position (Suppl. Fig. S1f).
We also moved from the candidate approach to a non-
biased genomic setting to identify the spectrum of NSUN5 
targets. To map NSUN5-dependent modified cytosine sites 
across the human transcriptome, we coupled bisulfite con-
version of cellular RNA with next-generation sequencing 
(bsRNA-seq) [44] in NSUN5-transfected LN229 glioma 
cells and empty-vector-transfected cells. Upon efficient res-
toration of NSUN5 expression, we observed that the only 
cytosine site in RNA that reached methylation levels of over 
90% following NSUN5 transfection was the C3782 posi-
tion of the 28S rRNA (empirical Bayes moderated t test, 
P = 0.033). Interestingly, the specificity of the approach was 
further confirmed by identifying that the only other methyl-
ated cytosine in 28S rRNA, the C4447 position correspond-
ing to the C4099 position in mouse 28S rRNA [23] and sug-
gested to be mediated by the other RNA-methyltransferase 
NSUN1 [40], was fully methylated in both empty-vector and 
NSUN5-transfected cells (Suppl. Fig. S5c). Thus, all these 
results indicate that NSUN5 is the human C3782 28S rRNA 
methyltransferase and that epigenetic silencing of NSUN5 in 
glioma cells prevents the formation of this chemical modifi-
cation in the rRNA transcript considered here.
To evaluate the structural impact of removing the 
methyl group of the C3782 position of the 28S rRNA, we 
simulated by means of Molecular Dynamics (MD) a sub-
region of the human 28S subunit around 5mC3782 (see 
“Materials and methods” and Fig. 4a–c). The simulation 
of the system with methylated C3782 (labelled r30A5mC) 
showed a stable methyl-π interaction between methylated 
C3782 and C3781 (Fig. 4d), while this interaction was lost 
in the unmethylated system (r30AC). The removal of the 
methyl group altered significantly the C3781-G3810 base 
pair and the conformation of the bulge at position C3809 
(Fig. 4d). The bulge interacts with a small hairpin (resi-
dues 3742–3778) which is located at the edge of the 28S 
subunit, exposed to the P-site of the ribosome (Fig. 4a–d). 
In the unmethylated system, the hairpin undergoes a 
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conformational change moving away from the P-site cav-
ity, showing an average displacement of 2.8 Å with respect 
to the methylated form (Fig. 4e). The role of this small 
hairpin is to interact directly through several residues with 
the tRNA molecule at the P-site, and even with the mRNA 
[13], being crucial to ensure the structural stability of the 
tertiary complex rRNA–tRNA–mRNA (Fig. 4f). The dis-
tortion on the hairpin observed in the simulation upon the 
removal of the methyl group (r30AC system) might be suf-
ficient to impair normal protein synthesis by altering the 
P-site conformation.
Fig. 3  NSUN5 epigenetic inactivation abrogates the methylation 
of the C3782 position of human 28S rRNA. a Top, RNA sequence 
alignment of the conserved human 28S rRNA C3782 position (black 
square) in the corresponding 26S, 25S and 28S rRNAs orthologues 
from C. elegans, S. cerevisiae and M. musculus. Below, Protein 
sequence alignment of human NSUN5 with its recognized rRNA 
5-methylcytosine RNA-methyltransferase orthologues in C. Elegans, 
S. Cerevisiae and M. musculus. Highlighted in black and grey the 
identical and physicochemically similar (scoring > 0.5 in the Gonnet 
PAM 250 matrix) residues, respectively. The aligned region includes 
the RNA-methyltransferase domain. b NSUN5 interaction with 28S 
rRNA. Total extracts from LN229 cells, either transfected with empty 
vector (EV) or NSUN5 were immunoprecipitated with an anti-Flag 
antibody (left panel), followed by analysis of the retrieved RNA by 
quantitative RT-PCR (right panel). c RNA bisulfite sequencing of the 
28S rRNA in glioma cells lines according to NSUN5 epigenetic sta-
tus. Cytosines are represented as short vertical lines and the C3782 
site is represented as a long black arrow. Single clones are shown for 
each sample. Presence of an unmethylated or methylated cytosine is 
indicated by a white or black square, respectively. d RNA bisulfite 
sequencing of the 28S rRNA in empty-vector (EV) and NSUN5-
transfected LN229 and A172 glioma cells. e RNA bisulfite sequenc-
ing of the 28S rRNA in scramble and NSUN5-shRNA-depleted 
DBTRG-05MG and CAS-1 glioma cells. For CAS-1, western-blot to 
show efficient NSUN5 depletion is shown above
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Fig. 4  Methylation of the C3782 position of human 28S rRNA medi-
ates the structural stability of the tertiary complex rRNA–tRNA–
mRNA and its loss leads to a structural distortion at the edge of the 
28S subunit in the P-site cavity. a Structure of the Human 80S ribo-
some taken from PDB code 6EK0. Proteins and RNA molecules 
are depicted in light-blue and white cartoons respectively, while 
Mg2 + are represented by pink spheres. b System considered in the 
MD simulations: 30 Å around residue C3782, which is depicted by 
its van der Waals radii (see “Materials and methods”). c Residues 
constrained at the experimental positions (nucleobases in green and 
backbone in orange), and residues completely free to move during the 
simulation (violet). d Local (left) and “long-range” (right) structural 
distortions observed in MD simulations after removal of the methyl 
group at position C3782 of the 28S subunit. Two representative 
structures taken from the simulations were aligned and overlapped 
to highlight structural differences. Methyl–π interaction is lost on 
the unmethylated system (r30AC, red), leading to a significant con-
formational change in the hairpin defined by residues 3754–3778. e 
Root-Mean-Squared-Deviation (RMSD) of the heavy atoms in the 
P-site hairpin (residues 3754–3778) along time. The hairpin in the 
r30A5mC system adopted a conformation in average 5.4 ± 0.8 Å apart 
from the cryoEM structure, while the unmethylated systems (r30AC) 
deviates 8.2 ± 1.2 Å. f Eukaryotic 80S ribosome taken from the cry-
oEM structure (5.5 Å-resolution) deposited with the PDB code 4V6I, 
highlighting the interaction between the P-site hairpin (nucleobases 
in green and backbone in orange), the tRNA (violet), and the mRNA 
(red)
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NSUN5 epigenetic loss restrains overall protein 
synthesis
We did not observe major effects in ribosome distribution, 
rRNA maturation and total rRNA levels comparing empty-
vector and NSUN5-transfected LN229 cells (Suppl. Fig. 
S5d and e); thus, we wondered about more specific ways 
that NSUN5 and C3782 loss could affect protein levels in 
cancer cells. Although global translation rates are generally 
increased in cancer cells [45], tumors may encounter hostile 
microenvironments during their growth due to various con-
ditions such as hypoxia, nutrient deprivation, and genotoxic 
stress [24]. One way that cancer cells survive in such stress 
settings is to reduce overall translation, thereby prevent-
ing this highly energy-consuming process and avoiding the 
accumulation of damaged and misfolded proteins [45]. Thus, 
we wondered whether the loss of the methylated site in the 
28S rRNA mediated by NSUN5 epigenetic inactivation in 
glioma cells could act in this manner. To measure global 
protein synthesis, we quantified the incorporation of O-pro-
pargyl–puromycin (OP–Puro) into nascent proteins [5] in 
our experimental models. Using  H2O2 in the medium to pro-
duce oxidative stress, we found that the three glioblastoma 
cell lines harboring NSUN5 epigenetic loss (LN229, A172, 
and KS1) show overall lower global protein synthesis than 
the three NSUN5 unmethylated cell lines (DBTRG-05MG, 
MO59 J and CAS-1) (Fig. 5a). Importantly, the transfection-
mediated recovery of NSUN5 expression in the NSUN5 
epigenetically deficient LN229 cells significantly increased 
global protein synthesis (Fig. 5b). Upon another stress con-
dition, nutrient deprivation, the NSUN5 epigenetically defi-
cient LN229 cells transfected with the empty vector also 
showed low overall level of protein synthesis, whereas the 
transfection-mediated recovery of NSUN5 expression sig-
nificantly increased global protein synthesis (Fig. 5c). Simi-
lar results were obtained using [3H] leucine incorporation to 
measure global protein synthesis: the restoration of NSUN5 
activity in the epigenetically inactivated LN229 cell signifi-
cantly enhanced [3H] leucine incorporation and, thereby, 
global protein synthesis (Fig. 5b, c). NSUN5 shRNA-medi-
ated downregulation in the NSUN5 unmethylated CAS-1 
cell line had the opposite effect (Suppl. Fig. S5f). Overall, 
the results indicate that the transcriptional inactivation of 
NSUN5 by promoter CpG island and the mediated loss of 
methylated C3782 in 28S rRNA were associated with a 
restriction of overall protein synthesis.
NSUN5 epigenetic loss promotes a specific mRNA 
translational program for stress survival
It is appropriate to mention that, in addition to the inhibi-
tion of global protein synthesis described above, human 
tumors manifest another method for coping with cellular 
stress: the activation of alternative translational programs 
that are involved in the adaptive response to stress [24, 45]. 
To identify the existence of a candidate translational pro-
gram that directly depends on the loss of C3782 28S rRNA 
methylation upon NSUN5 epigenetic inactivation, we per-
formed both RNA-Seq and Ribo-seq analyses comparing 
empty-vector and NSUN5-transfected LN229 cells in the 
absence of  H2O2 stress. Glioma cells with restored NSUN5 
expression presented RNA abundance differences in less 
than 2% transcripts (255 upregulated and 244 downregu-
lated) remaining the 98% transcript abundance unchanged 
(absolute log2 fold change > 2) (Fig. 5d).
On the other hand, we analyzed the differences in the 
ribosome occupancy for the same conditions. We observed 
7.2% transcripts (1028 over-occupied and 2009 down-occu-
pied) with ribosome profiling differences (P value < 0.01 
and absolute log2 fold change > 0.5) (Fig. 5d). RNAs with 
enhanced translational efficiency were defined as those 
unaltered in the RNA-seq, but upregulated in Ribo-seq [5, 
51]. We identified 1987 transcripts with greater transla-
tion efficiency in the LN229 empty-vector-transfected cells 
(harboring NSUN5 epigenetic silencing) in comparison 
with NSUN5-transfected cells (Fig. 5d, Suppl. Table S1). 
We confirmed these observations by calculating transla-
tion efficiency values from over-dispersion analysis of both 
RNA-seq and Ribo-seq measurements by applying a general 
linear model (GLM) (Suppl. Methods).
We observed no over-representation of known regula-
tory motifs in the 5′-untranslated regions of these NSUN5-
controlled transcripts, which included CAP-independent 
elements, such as internal ribosome entry sites (IRES), or 
CAP-dependent elements such as G-quadruplexes, cyto-
sine-enriched regulator of translation (CERT), terminal 
oligopyrimidine tract (TOP), pyrimidine-rich translational 
sequences (PRTE) and upstream Open Reading Frames 
(uORFs) (P value = 0.8722 Welch Two sample t test) (Suppl. 
Fig. S6a). The use of a bicistronic reporter plasmid encoding 
both Firefly (IRES) and Renilla (CAP) luciferases further 
demonstrated the effect of NSUN5 on CAP-dependent and 
CAP-independent translation (Fig. 5e). To better character-
ize the described set of 1987 RNAs with significantly higher 
translational efficiency in NSUN5 epigenetically deficient 
cells, we developed a gene functional annotation by perform-
ing gene set enrichment analysis (GSEA). Using KEGG and 
GO signature collections, we observed an over-representa-
tion of cellular pathways and biological terms related to can-
cer, cell cycle, and the ribosome. Following the GSEA and 
sequence motifs recognition analysis described in “Materials 
and methods”, we applied a hypergeometric test with a FDR 
adjusted P value < 0.05 over the TE candidate genes using 
DAVID and GSEA signature database collections. Most 
strikingly, we noted an enhancement of ontologies related to 
cellular response to stress and metabolic adaptation (Fig. 5f).
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To confirm this scenario, in which NSUN5 epigenetic 
silencing promotes a global reduction in protein synthe-
sis, but a specific protein production program emerges 
that is associated with enhanced translational efficiency 
to deal with cellular stress, we carried out stable isotopic 
labeling of amino acids in cell culture (SILAC) in empty-
vector-transfected LN229 cells in comparison with NSUN5 
stably transfected LN229 cells. At the level of resolution 
employed in the SILAC analyses, 128 proteins were identi-
fied that had significantly different expression upon NSUN5 
transfection in LN229 cells (Suppl. Table S2). With the aim 
to improve the characterization of the proteins with signifi-
cantly different expression upon NSUN5 transfection, we 
developed a gene functional annotation by performing gene 
set enrichment analysis (GSEA). Following the GSEA and 
sequence motifs recognition analysis described in “Materi-
als and methods”, we applied a hypergeometric test with 
an FDR adjusted P value < 0.05 over the candidate genes 
using DAVID and GSEA signature database collections. 
Using KEGG and GO signature collections, we observed 
Fig. 5  NSUN5 epigenetic loss is associated with depletion of global 
protein synthesis and the emergence of a stress-response transla-
tional program. a NSUN5 unmethylated glioma cell lines DBTRG-
05MG, MO59J, and CAS-1 show higher overall protein synthesis 
assessed by OP-Puro under oxidative stress (100  mM  H2O2) than 
the NSUN5 methylated cells (A172, LN229 and KS-1). b Restora-
tion of NSUN5 function by transfection in epigenetically inactive 
LN299 cells increases overall protein synthesis under oxidative stress 
(100 mM  H2O2) assessed by OP-Puro. Enhancement of global protein 
synthesis upon NSUN5 recovery in LN299 cells is also observed by 
the [3H] leucine incorporation assay. c Similar results were obtained 
upon nutrient deprivation. d Comparison of the total RNA (RNA-
seq) and ribosome-protected RNA (Ribo-seq) deep-sequencing pro-
files to identify those RNAs with enhanced translational efficiency in 
NSUN5 deficient cells. 1987 RNAs that did not change in the RNA-
seq of LN229 cells upon NSUN5-transfection were upregulated in the 
Ribo-seq of empty-vector-transfected cells indicating enhanced trans-
lational efficiency. e NSUN5 affects both CAP-dependent and CAP-
independent translation according to the use of a reporter plasmid 
encoding for Firefly (IRES) and Renilla (CAP) luciferases. f Gene set 
enrichment analysis (GSEA) of the RNAs with increased translational 
efficiency in NSUN5 deficient cells (hypergeometric test with a FDR 
adjusted P value < 0.05)
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an over-representation of cellular pathways and biological 
terms related to cell signaling, response to stress by mis-
match repair and RNA processing (Suppl. Fig. S5g). Most 
proteins (73%; 94 of 128) were found to be upregulated upon 
restoration of NSUN5, whereas the remaining 27% (34 of 
128) were downregulated (Suppl. Table S2). Western-blot 
validation of three downregulated proteins upon NSUN5 
transfection is shown in Suppl. Fig. S5h. Thus, these data are 
consistent with the idea that the loss of NSUN5 in glioma 
cells restricts general protein synthesis. They also suggest 
the existence of a selective synthesis of specific proteins 
in the context of NSUN5 deficiency. In this regard, 26% 
(9 of 34) of these proteins were derived from RNAs that 
showed increased translational efficiency upon NSUN5 loss 
(Fig. 5d). We selected one of these targets, the stress-acti-
vated protein NQO1 [9], for western-blot and quantitative 
reverse transcription–PCR analyses, which confirmed that 
its NSUN5 regulation occurred at the mRNA translational 
level and was not associated with a difference in RNA levels 
(Fig. 6a). In addition, NQO1 was enriched in the polysome 
fraction of the empty-vector LN229 cells (where NSUN5 
is epigenetically silenced) in comparison with NSUN5-
transfected LN229 cells (Fig. 6b). Further development of 
additional RNA-seq experiments comparing empty-vector 
and NSUN5-transfected LN229 cells, but in the presence of 
 H2O2 stress, confirmed that NSUN5 transfection had almost 
no effect in the transcriptome, remaining 99.5% of the tran-
scripts unchanged (Suppl. Table S3). Ribo-seq analysis in 
these cells, undergoing  H2O2 stress, further confirmed that 
NQO1 showed greater translation efficiency in the LN229 
empty-vector-transfected cells (having NSUN5 epigenetic 
loss) in comparison with NSUN5-transfected cells (Suppl. 
Table S1). We also performed RNA-seq in the absence of 
 H2O2 in another glioblastoma cell line, A172, that it also 
shows NSUN5 epigenetic inactivation obtaining near identi-
cal results: 99% of transcripts levels were unchanged upon 
NSUN5 transfection, including NQO1 (Suppl. Table S3).
The above-described scenario was also validated in 
loss-of-function experiments. To identify the existence of 
a candidate translational program that directly depends on 
NSUN5 loss, we performed both RNA-Seq and Ribo-seq 
analyses in NSUN5 shRNA-depleted vs scramble shRNA 
DBTRG-05MG cells. Glioma cells with depleted NSUN5 
expression presented RNA abundance differences in less 
than 1% transcripts, remaining the 99% transcript abundance 
unchanged (absolute log2 fold change > 2) (Suppl. Fig. S6b 
and Suppl. Table S4), whereas for ribosome occupancy, 
we observed a 2.2% transcripts with ribosome profiling dif-
ferences (absolute log2 fold change > 0.5) (Suppl. Fig. S6b 
and Suppl. Table S4). RNAs with enhanced translational 
efficiency were defined as those unaltered in the RNA-seq, 
but upregulated in Ribo-seq [5, 51]. We identified 787 
transcripts with greater translation efficiency in NSUN5 
shRNA-depleted DBTRG-05MG cells in comparison 
with scramble shRNA cells (Suppl. Fig. S6b and Suppl. 
Table S4). We confirmed these observations by calculating 
translation efficiency values from over-dispersion analysis 
of both RNA-seq and Ribo-seq measurements by applying 
a general linear model (GLM) (Suppl. Methods).
With the aim to improve the characterization of the 
described set of 787 RNAs with significantly higher transla-
tional efficiency in NSUN5 shRNA-mediated deficient cells, 
we developed a gene functional annotation by performing 
gene set enrichment analysis (GSEA). Using KEGG and GO 
signature collections, we observed an over-representation 
of cellular pathways and biological terms related to cancer 
and the ribosome. Following the GSEA and sequence motifs 
recognition analysis described in “Materials and methods”, 
we applied a hypergeometric test with an FDR adjusted P 
value < 0.05 over the TE candidate genes using DAVID and 
GSEA signature database collections. As we had previ-
ously described for the LN229 model (Fig. 5f), we noted an 
enhancement of ontologies related to cellular response to 
stress and metabolic adaptation (Suppl. Fig. S6c). NQO1, 
that was characterized above as having an enhanced trans-
lational efficiency (Suppl. Table S1 and Fig. 6a, b) and 
overexpression (Suppl. Table S2 and Fig. 6a) in LN229 
cells with NSUN5 epigenetic loss, was also identified as a 
target of enhanced translational efficiency in DBTRG-05MG 
cells with shRNA-mediated depletion of NSUN5 (Suppl. 
Table S4). Western-blot and quantitative reverse transcrip-
tion–PCR analyses confirmed that NQO1 upregulation at the 
protein level in NSUN5 depleted cells was not associated 
with a difference in RNA levels (Suppl. Fig. S6d). Alto-
gether, these data are consistent with the idea that the loss 
of NSUN5 in glioma cells restricts general protein synthesis 
while activating the selective synthesis of specific stress-
related proteins such as NQO1.
NSUN5 DNA methylation‑associated silencing 
confers sensitivity to drugs that target NQO1
The finding that NSUN5 epigenetic silencing was associated 
with NQO1 overexpression prompted us to study whether 
these glioma cells might be more vulnerable to compounds 
targeting this particular stress-related protein. Drugs that 
generate reactive oxygen species have been suggested to 
be useful for pushing cancer cells over an oxidative stress 
threshold and into cell death [15]. In this regard, deoxynybo-
quinone (DNQ) and isobutyl–deoxynyboquinone (IB-DNQ) 
are NQO1 bioactivatable substrates that cause the produc-
tion of large amounts of ROS that cannot be tolerated by the 
cancer cells, leading to their death [19, 27, 30]. Thus, we 
assessed whether an enhanced growth inhibitory effect of 
these compounds was dependent on NSUN5 methylation. 
First, we demonstrated by western-blot analyses that the 
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three studied glioma cell lines with NSUN5 hypermethyla-
tion (LN229, A172, and KS-1) showed high levels of NQO1, 
whereas minimal expression of NQO1 was observed in the 
three NSUN5 unmethylated cell lines (DBTRG-05MG, 
MO59 J, and CAS-1) (Fig. 6c). These data confirmed the 
above-described role of NSUN5 expression in the regula-
tion of NQO1 protein levels (Fig. 6a). Most importantly, 
the determination of the corresponding IC50 values, accord-
ing to the SRB assay for cell viability, showed that NSUN5 
hypermethylated glioma cells were significantly more sen-
sitive to the DNQ and IB-DNQ drugs than the NSUN5 
unmethylated glioma cell lines (z test, P < 0.0001) (Fig. 6d). 
Furthermore, we extended these assays to NSUN5 meth-
ylated LN229 glioma cells, where we have exogenously 
restored NSUN5 activity and thus depleted the NQO1 pro-
tein (Fig. 6a). We observed that upon NSUN5 transfection 
the cells become significantly more resistant to the NQO1 
bioactivatable substrate in comparison to empty-vector-
transfected cells (z test, P < 0.001) (Fig. 6e). Similar results 
were also found in vivo for cancer cells injected orthotopi-
cally in the brain of nude mice (Fig. 6f). The use of the 
NQO1 bioactivatable substrate increased survival in those 
Fig. 6  NSUN5 epigenetic silencing activates stress-related protein 
and confers growth inhibition sensitivity to NQO1-targeting mol-
ecules. a Validation of NSUN5 translational regulation of the iden-
tified stress-related target NQO1 expression at the RNA level deter-
mined by RNA-seq counts (left) and real-time quantitative PCR 
(middle) do not change upon NSUN5 transfection, but NQO1 expres-
sion decreased at the protein level (right) upon NSUN5 restoration. 
b qPCR shows enrichment of the NQO1 transcript in the polysome 
fraction of the empty-vector LN229 cells in comparison to NSUN5 
transfected-LN229 cells. c NQO1 expression levels in glioma cell 
lines determined by western blot according to NSUN5 methylation 
status. d IC50 determination using the SRB assay in the glioma cell 
lines grouped by NSUN5 methylation status. Black dashed curves 
represent the 95% confidence band for each group. Glioma cells har-
boring NSUN5 methylation-associated NQO1 overexpression (A172, 
LN229 and KS-1) show increased sensitivity to deoxynyboquinone 
(DNQ) and IB-DNQ in comparison to NSUN5 unmethylated cells 
(DBTRG-05MG, MO59  J, and CAS-1). Drug-response curves were 
generated using GraphPad Prism software and analyses were per-
formed with the drc R package. For each cell line and the drug, we 
fit a four-parameter generalized log-logistic model. Comparison of 
the IC50 values calculated from the slopes were obtained by means 
of a z test (P < 0.0001). e IC50 determination using the SRB assay 
in NSUN5-transfected LN299 cells in comparison with empty-vector-
transfected cells (EV) shows enhanced resistance to DNQ-mediated 
growth inhibition in the cells with restored NSUN5 expression. Com-
parison of the IC50 values calculated from the slopes was obtained 
by means of a z test (P < 0.001). f Kaplan–Meier analysis of Survival 
according treatment conditions (IB-DNQ treated vs mock group) in a 
set of mice models with implanted tumors derived from the NSUN5 
methylated cell line A172 (left) or the NSUN5 unmethylated cell line 
DBTRG (right). Significance of the log-rank test is shown. Results of 
the univariate Cox regression analysis are represented by the hazards 
ratio (HR) and 95% confidence interval (CI)
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nude mice with tumors originated from NSUN5 hypermeth-
ylated A127 glioma cells in comparison with the mock-
treated group (Fig. 6f), whereas no differences in survival 
between drug and mock treatment were observed for mice 
carrying tumors derived from the NSUN5 unmethylated 
cell line DBTRG-05MG (Fig. 6f). Thus, the occurrence of 
NSUN5 methylation pinpoints glioma cells that are more 
sensitive to the cytotoxic effect of NQO1 substrates.
NSUN5 epigenetic loss is a hallmark of human 
primary gliomas with good clinical outcome
Once we had determined in glioma cell lines and mouse 
models the effects of NSUN5 epigenetic silencing, we 
studied the impact of NSUN5 promoter CpG island 
hypermethylation in human primary gliomas. The analy-
ses of the collection of human gliomas available from The 
Cancer Genome Atlas (TCGA) (https ://tcga-data.nci.nih.
gov/tcga/), which used the same DNA methylation micro-
array platform as that used here for our initial Sanger cell 
line screening, showed the presence of NSUN5 promoter 
CpG island methylation in 28% (190 of 681) of gliomas 
of different grades (Fig. 7a and Suppl. Table S5). TCGA 
RNA-sequencing data showed that NSUN5 hypermethyla-
tion was associated with transcript downregulation across 
glioma samples (Spearman’s rank correlation, ρ = − 0.7, 
P < 10−5) (Fig. 7b). The histological grade based on the 
degree of anaplasia, as set out in the World Health Organi-
zation (WHO) Classification of Tumors of the Central Nerv-
ous System, has a major effect on the natural history of the 
Fig. 7  NSUN5 epigenetic inactivation occurs in human primary 
gliomas in association with good clinical outcome. a Percentage of 
NSUN5 methylation in the TCGA data set of primary tumors accord-
ing to cancer type (top) and according to the cellular grade of the 
glioma (down). b NSUN5 promoter CpG island methylation is asso-
ciated with the loss of the transcript among all cellular grades in pri-
mary glioma, in low-grade glioma and in glioblastoma. c Kaplan–
Meier analysis of overall survival (OS) across overall glioma grades 
and in low- and high-grade glioma with respect to NSUN5 methyla-
tion status. Significance of the log-rank test is shown. Results of the 
univariate Cox regression analysis are represented by the hazards 
ratio (HR) and 95% confidence interval (CI). d Kaplan–Meier analy-
sis of OS in IDH1 wild-type gliomas according to NSUN5 methyla-
tion status. e Kaplan–Meier analysis of OS in gliomas without 1p/19q 
deletion according to NSUN5 methylation status. f Kaplan–Meier 
analysis of OS in gliomas with unmethylated MGMT according to 
NSUN5 methylation status. For all graphs, the P value corresponds to 
the Log-Rank test. Cox regression univariate analysis is represented 
by HR with a 95% CI
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disease. Low-grade gliomas (LGGs; grades I, II, and III) 
have a more favorable prognosis, whereas the high-grade 
gliomas (grade IV), also known as glioblastoma multiforme 
(GBM), have an extremely unfavorable outcome [32, 50]. 
We observed the enrichment of NSUN5 hypermethylation in 
low-grade gliomas (34%, 180 of 527) relative to GBM (6%, 
10 of 154) (Fisher’s exact test, P = 3.8  10−9) (Fig. 7a). TCGA 
RNA-sequencing data showed NSUN5 hypermethylation to 
be associated with transcriptional downregulation in low- 
and high-grade gliomas (Fig. 7b). Beyond adult gliomas, we 
also detected NSUN5 hypermethylation in pediatric brain 
tumors, such as diffuse intrinsic pontine glioma (DIPG) 
(50%, 5 of 10) and medulloblastoma (25%, 2 of 8). Impor-
tantly, we were able to obtain RNA from three DIPG tumors, 
where we observed that the two NSUN5 hypermethylated 
cases showed hypomethylation of the C3782 position of 
the 28S rRNA, while the NSUN5 unmethylated patient dis-
played high levels of rRNA methylation at this site (Suppl. 
Fig. S6e and f).
Given the known relation between glioma grade and 
clinical outcome, we wondered whether NSUN5 hyper-
methylation also conferred any prognostic value. We 
observed that NSUN5 hypermethylation was associated 
with increased overall survival (OS) in all glioma grades 
in the TCGA cohort [log-rank; P < 10−5; hazard ratio 
(HR) = 5.17, 95% CI = 2.78–9.61] (Fig. 7c). Interestingly, 
the value of NSUN5 hypermethylation as a predictor of bet-
ter outcome was observed for low- and high-grade gliomas 
(Fig. 7c). NSUN5 hypermethylation was associated with 
higher OS in LGG (log-rank; P = 0.044; HR = 2.05; 95% 
CI = 1.01–4.18) and GBM (log-rank; P = 0.012; HR = 8.26; 
95% CI = 1.15–59.50) (Fig. 7c). These data are particularly 
relevant in the context of GBM because of its dismal out-
come in 90% of patients. However, the remaining 10% of 
individuals are long-term survivors, for whom the molecular 
factors involved have not been fully identified [32, 50].
Low levels of the NSUN5 RNA transcript were also asso-
ciated with increased OS in the TCGA cohort (log-rank; 
P < 10−5; HR = 4.57; 95% CI = 2.40–9.04) (Suppl. Fig. S7a). 
Upon division by grade, low levels of NSUN5 RNA tran-
script were also associated with increased OS in LGG (log-
rank; P = 0.014; HR = 2.37; 95% CI = 1.16–4.84) (Suppl. 
Fig. S7b). A trend between low expression of NSUN5 and 
shorter OS was found in GBMs, but due to the small number 
of cases with low expression (n = 2) according to the estab-
lished cutoff, it lacked statistical power (Suppl. Fig. S7c).
We confirmed the TCGA glioma findings in a newly 
obtained validation cohort of 115 primary gliomas (Suppl. 
Table S5), where NSUN5 methylation status was determined 
by the pyrosequencing assay: NSUN5 promoter hypermeth-
ylation was associated with and increased OS (log-rank; 
P = 0.043; HR = 1.90; 95% CI = 1.01–3.58) and extended 
progression-free survival (PFS) (log-rank; P = 0.010; 
HR = 1.95; 95% CI = 1.16–3.27) (Fig.  7d). We further 
expanded this initial validation cohort with the inclusion 
of two independent glioma cohorts of 303 patients, where 
NSUN5 methylation status is available from the same DNA 
methylation microarray used in the TCGA glioma cases 
[1, 22]. Suppl. Table S5 shows the clinicopathological and 
molecular characteristics of the overall extended validation 
cohort. Related to clinical outcome in this large validation 
cohort, only PFS was available from the three set of cases 
(pyrosequencing plus the two data-mined cohorts), and thus, 
it was the assessed variable. We confirmed that NSUN5 pro-
moter hypermethylation was associated with increased PFS 
(log-rank; P value  10−5; HR = 3.03; 95% CI = 2.35–3.74) 
(Fig. 7e). Importantly, the impact of NSUN5 methylation 
on PFS is maintained when the glioma validation samples 
are divided into grades. NSUN5 methylation is associated 
with extended PFS in low-grade gliomas (LGG, n = 183) 
(log-rank; P value  10−5; HR = 5.07; 95% CI = 3.46–7.41) 
(Fig. 7e) and glioblastoma (GBM, n = 235) (log-rank; P 
value  10−5; HR = 2.14; 95% CI = 1.58–2.91) (Fig. 7e).
We examined whether other genetic and epigenetic altera-
tions of clinical relevance in glioma [32, 50] helped define 
patients with NSUN5 methylation-associated extended sur-
vival. In this regard, the presence of IDH1 mutations in glio-
mas is known to be a predictor of improved outcome [32, 50]. 
We found this to be the case for the gliomas included in the 
TCGA repository: IDH1 mutations are associated with longer 
OS (Suppl. Fig. S8a). Interestingly, for those cases with a 
wild-type IDH1, which are all supposed to have an adverse 
prognosis, the presence of NSUN5 hypermethylation high-
lighted a subset of cases with long OS (Suppl. Fig. S8a). A 
similar clinical observation than the one observed for IDH1 
mutants was found related to the co-deletion of chromosome 
arms 1p and 19q, another predictor of good outcome [32, 
50], that it was also associated with longer OS in the gliomas 
from the TCGA repository (Suppl. Fig. S8b). Importantly, 
for those patients without 1p/19q co-deletion, which are all 
expected to have a poor outcome, NSUN5 hypermethylation 
pinpointed a subgroup with improved OS (Suppl. Fig. S8b). 
Interestingly, an additional complementary molecular sce-
nario was discovered related to another key marker in human 
glioma that is also used in clinical practice: the DNA repair 
enzyme MGMT [32, 50]. Epigenetic inactivation of MGMT 
is linked to an enhanced response to chemotherapy-alkylating 
agents and increased OS in gliomas [10, 17]. We found this to 
be the case for the TCGA gliomas: MGMT hypermethylation 
is associated with longer OS (Suppl. Fig. S8c). In addition, 
here again, for those gliomas unmethylated at MGMT, which 
are supposed to show poor outcome, NSUN5 hypermeth-
ylation defined a subset with extended OS (Suppl. Fig S8c). 
The above-described TCGA results were mostly confirmed 
in our expanded glioma validation cohort. First, in this set of 
cases, we confirmed that the IDH1 mutation, the co-deletion 
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of chromosome arms 1p and 19q and MGMT hypermethyla-
tion were all associated with longer PFS (Suppl. Fig. S8d, 
e, and f). Importantly, for those patients without 1p/19q co-
deletion, NSUN5 hypermethylation pinpointed a subgroup 
with improved PFS (Suppl. Fig. S8e). Related to IDH1 muta-
tional status, we observed a trend between NSUN5 hyper-
methylation and longer PFS in the cases with a wild-type 
IDH1 that did not reach statistical significance (Suppl. Fig. 
S8d). Interestingly, NSUN5 hypermethylation defined a sub-
set with extended PFS for both MGMT unmethylated and 
hypermethylated patients (Suppl. Fig. S8f).
For both TCGA and validation cohorts, we observed that 
NSUN5 methylation was associated with other biomarkers 
of clinical benefit such as IDH1 mutation (Fisher’s exact test 
P < 10−5), co-deletion of 1p/19q (Fisher’s exact test P < 10−5), 
and MGMT methylation (Fisher’s exact test P < 10−5) (Suppl. 
Table S5). Importantly, all these three last molecular markers 
are also significantly associated between them (IDH1 muta-
tion/co-deletion 1p/19q, Fisher’s exact test P < 10−5; IDH1 
mutation/MGMT methylation, Fisher’s exact test P < 10−5; 
co-deletion 1p/19q/MGMT methylation, Fisher’s exact test 
P < 10−5) (Suppl. Table S6). It is also worth to mention that 
NSUN5 methylation was not associated with the glioma CpG 
island methylator phenotype (gCIMP) (Fisher’s exact test, 
P = 0.094) (Suppl. Table S5) (Suppl. Methods), a common 
phenomenon in IDH1 mutant patients [29]. As expected, 
the presence of the gCIMP phenotype in the TCGA glioma 
data set is associated with improved clinical outcome (Suppl. 
Fig. S9a). Strikingly, when we stratified the TCGA data set 
according to gCIMP status and NUSN5 methylation, we 
observed that for those cases with a lack of the gCIMP phe-
notype, which are all supposed to have a poor clinical out-
come, the presence of NSUN5 hypermethylation highlighted 
a subset of cases with long overall survival (Suppl. Fig. S9b).
Finally, and most importantly, to determine the value of 
NSUN5 methylation as a candidate independent biomarker, 
we performed multivariate analysis for NSUN5 methyla-
tion status and the described known biomarkers of clinical 
outcome (IDH1 mutational, 1p/19q co-deletion and MGMT 
methylation status) for the both studied glioma cohorts. 
Multivariate Cox regression analysis showed that NSUN5 
hypermethylation was an independent predictor of OS in 
the TCGA glioma cohort (HR = 0.50; 95% CI = 0.26–0.94; 
P = 0.032) (Fig. 8a) and an independent predictor of PFS 
in the interrogated validation cohort of glioma patients 
(HR = 0.46; 95% CI = 0.35–0.61; P < 0.001) (Fig. 8b).
Discussion
More than 100 distinct nucleotide modifications have been 
reported in the RNA molecule across the range of all life 
forms [10, 11, 27], many of which are also present in human 
RNA molecules such as N6-methyladenosine, N1-methyl-
adenosine, pseudouridine, or 5-methylcytosine [10, 11, 27]. 
The chemical modifications of RNA, referred to in a global 
context as the epitranscriptome, carry out functions criti-
cal to cellular homeostasis, contributing to RNA stability, 
export, localization, structure, splicing, processing, recod-
ing, targeting, and translation [8, 11, 14, 34]. We are at the 
dawn of our understanding of how disruption of the epitran-
scriptome can initiate and promote tumorigenesis, but the 
emerging findings indicate that altered RNA modification 
patterns play a fundamental role in cancer.
The occurrence of mutations in the pseudouridine syn-
thase DKC1 in X-linked dyskeratosis congenita (X-DC), a 
disorder characterized by cancer susceptibility [18], is par-
ticularly interesting, because it directly affects a key cellu-
lar element, the ribosome. DKC1 is the pseudouridine syn-
thase that mediates the introduction of this modified base 
in ribosomal RNA [37, 53]. Mice that are hypomorphically 
mutant for DKC1 exhibit decreased pseudouridine in their 
RNAs and a defect in translation that particularly affects 
mRNAs containing Internal Ribosome Entry Sites (IREs) 
[3, 4, 18, 21, 53]. Translational control is also impaired in 
human X-DC patients [3, 53]. These results indicate that 
ribosomes are not passive structures in cellular transforma-
tion, but actively contribute to the phenotype of cancer cells. 
This idea is also supported by the existence of specialized 
ribosomes and complex machineries associated with these 
structures and rRNAs [41, 42], in addition to the presence 
of mutations in ribosomal proteins in cancer-associated syn-
dromes [7]. Significantly for rRNA, in addition to pseudouri-
dine, another modification, that of 5-methylcytosine, seems 
to have a central regulatory role [31]. This RNA chemical 
modification also acts at the level of tRNAs, where loss of 
the 5-methylcytosine RNA-methyltransferase NSUN2 drives 
a global reduction in protein synthesis [5, 6, 34] and altered 
translational programs [5, 6], in a similar manner to that 
which occurs upon the loss of DKC1 [3, 4, 37, 53].
In this study, we combined genomic, epigenomic, and 
epitranscriptomic approaches to characterize the 5-methyl-
cytosine RNA methyltransferase, NSUN5, and showed how 
its epigenetic silencing produces a hypomethylation event at 
a particular position of the 28S rRNA that depletes the over-
all protein synthesis, but engages glioma cells in a particular 
translational program for survival under conditions of cellu-
lar stress. Interestingly, we also show by molecular dynamics 
that the methylation of the C3782 position of human 28S 
rRNA could mediate the structural stability of the tertiary 
complex rRNA–tRNA–mRNA, leading it loss to a structural 
distortion at the edge of the 28S subunit in the P-site cavity 
that might impair the physiological protein synthesis [28].
The observed “translational paradox”, the emergence of 
a translational program in the context of globally depleted 
protein production, is a well-known mechanism used by cells 
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to exert a strong and timely influence on gene expression to 
deal with stress conditions [24]. As tumors progress, they 
encounter many obstacles and unfriendly environments that 
frequently produce oxidative, replicative, genotoxic, proteo-
toxic, or metabolic stress [45]. Even oncogenic mutations 
that promote tumorigenesis in the early stages subsequently 
become a nuisance if they generate high levels of ROS that 
are toxic to cancer cells [24]. One of the main adaptations 
of tumors to these conditions is the global inhibition of pro-
tein synthesis that shuts down a highly energy-demanding 
process and at the same time prevents the accumulation of 
misfolded or damaged proteins [45]. However, there is a 
simultaneous enabling of translation of selected mRNAs 
that are vital for the adaptive cell response [24]. Another 
illustrative case is provided by NQO1, a multifunctional 
antioxidant enzyme regulated by the Keap1/Nrf2/ARE path-
way [9], whose translational efficiency increases upon the 
loss of NSUN5 in glioma, as reported here, to overcome 
the many types of oxidative stress encountered by these 
transformed cells. NSUN5 methylation-mediated overex-
pression of NQO1 can also constitute a therapeutic oppor-
tunity in these gliomas, because they become more sensitive 
to ROS-induced death upon the use NQO1-bioactivatable 
molecules [19, 27, 30]. Thus, NSUN5 DNA methylation-
associated inactivation, through its linked defect in 28S 
rRNA methylation, represents a bona fide mechanism that 
explains how human gliomas adapt to challenging cellular 
stress conditions by depleting overall synthesis while also 
promoting specific translational programs. Furthermore, 
although we did not observe NSUN5 genomic defects in 
the studied models, more comprehensive studies are required 
to discard additional genetic alterations.
This role of NSUN5 epigenetic silencing in the toleration 
of cellular stress settings resembles another key molecular 
event in gliomagenesis: the occurrence of IDH1 mutations. 
We have demonstrated that the loss of NSUN5 activity 
extends cell viability in vivo and in vitro, but it is associ-
ated with improved clinical outcome. In a similar manner, 
Fig. 8  Forest plots of the 
multivariable Cox regression 
analysis for clinical outcome 
in the glioma cohorts studied 
for NSUN5 methylation status 
taking into account different 
prognostic factors. P values 
(P) correspond to hazard ratios 
(HR), with a 95% of confidence 
interval (95%CI), associated 
with OS. Co-variables with 
associated P value under 0.05 
were considered as independent 
prognostic factor (*P < 0.05, 
**P < 0.01, ***P < 0.001). a 
Overall Survival (OS) multivar-
iate Cox regression analysis in 
the TCGA set of glioma patients 
(n = 497). b Progression-free 
survival (PFS) multivariate 
Cox regression analysis in 
the expanded validation set of 
glioma patients (n = 418)
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the loss of IDH1 normal catalytic activity contributes to 
gliomagenesis, but it is also associated with good OS. Once 
again, we can consider how cancer cells avoid death when 
confronted by damaging stress conditions, because, as we 
have shown for NSUN5, the disruption of IDH1 is another 
way of dealing with metabolic and hypoxic stress [33]. Thus, 
those patients with gliomas exhibiting NSUN5 epigenetic 
silencing, like those carrying IDH1 mutations, have tumor 
cells that probably are on the verge of death, whose last 
resort in their struggle to survive is to restrict overall protein 
synthesis and to instigate particular emergency translational 
programs to deal with multiple stress conditions.
In conclusion, NSUN5 loss in glioma provides a link 
between an epigenetic event, the promoter CpG island 
hypermethylation of its promoter, and an epitranscriptomic 
event, the hypomethylated status of the C3782 position of 
the human 28S rRNA. Most significantly, we have shown 
that NSUN5 inactivation is a likely pathway used by gli-
oma cells to overcome hostile stress conditions by restrain-
ing high energy-consuming global protein synthesis while 
stimulating the translation of adaptive proteins such as 
NQO1. These findings, if validated in larger sets of prospec-
tive clinical studies, might be useful for the management of 
glioma patients, because, in the context of a disease, whose 
prognosis is usually dismal, the NSUN5 epigenetic lesion 
contributes to identify those patients who are likely to have 
a good outcome.
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